Two faculty members from the University of Maryland School of Pharmacy (UMSOP) have received a $2.84 million grant from the National Institutes of Health (NIH) to explore a novel therapeutic strategy aimed at enhancing the efficacy of and reducing the toxicity of a widely used chemotherapy regimen for triple-negative breast cancer (TNBC).
The five-year R01 grant, titled “Impact of CAR and Nrf2 Dual Activation on Cyclophosphamide Bioactivation and Doxorubicin Detoxification,” was awarded to Hongbing Wang, PhD, professor and interim chair of the Department of Pharmaceutical Sciences (PSC), and Fengtian Xue, PhD, professor of PSC and associate dean for research.
Read the full story on the School of Pharmacy's News Center.